{"product_id":"assertiotx-marketing-mix","title":"Assertio Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Assertio’s product mix, pricing architecture, distribution channels, and promotion tactics combine to drive market performance—this preview highlights key takeaways, but the full 4Ps Marketing Mix Analysis delivers deep, editable insights, real-world data, and presentation-ready slides to save you hours and power strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Specialty Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssertio’s Diversified Specialty Portfolio centers on branded drugs in neurology, inflammation, and pain, with Indocin and Rolvedon as 2025 anchors; these brands contributed roughly $85M of the company’s $190M revenue in FY2024, supporting a 12% gross margin improvement from lifecycle interventions. The firm uses life-cycle management—label expansions, formulation tweaks, and commercial partnerships—to sustain market share and extend patent-life economics over the next 3–5 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRolvedon Injection Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe inclusion of Rolvedon (eflapegrastim) strengthens Assertio’s oncology supportive-care portfolio by targeting chemotherapy-induced neutropenia, a condition affecting ~16% of patients on myelosuppressive regimens per 2024 oncology data.\u003c\/p\u003e\n\u003cp\u003eRolvedon differentiates Assertio with a long-acting G-CSF injectable, offering once-per-cycle dosing vs daily filgrastim, improving adherence and clinic throughput.\u003c\/p\u003e\n\u003cp\u003eFinancially, Rolvedon contributed to Assertio’s injectable segment that grew ~28% YoY in 2024, signaling a strategic pivot to higher-value hospital and clinic-administered biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndocin Product Family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndocin, a top revenue driver for Assertio, generated about $42M in 2024 sales and is sold as suppositories and an oral spray for inflammatory conditions, targeting patients with swallowing or GI absorption issues. These delivery forms meet unmet needs that standard pills can miss, supporting adherence and niche market share. The specialty positioning reduces head-to-head generic pressure, preserving higher margins—gross margin ~65% in 2024—relative to commodity NSAIDs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology and Pain Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAssertio’s neurology and pain product mix centers on Cambia and Zipsor, positioned for acute migraine and short-term pain relief with faster absorption and stronger clinical pain-reduction versus many OTCs; Cambia drove roughly $45M in 2024 U.S. sales and Zipsor about $12M, preserving revenue stability.\u003c\/p\u003e\n\u003cp\u003eMaintaining these brands leverages Assertio’s clinician ties—over 2,200 neurology and pain clinic accounts in 2024—and supports targeted payer contracts and formulary placements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRapid absorption, proven clinical efficacy\u003c\/li\u003e\n\u003cli\u003e$57M combined 2024 U.S. revenue\u003c\/li\u003e\n\u003cli\u003e2,200+ specialist clinic relationships (2024)\u003c\/li\u003e\n\u003cli\u003eFocus on payer\/formulary access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Asset Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAssertio buys FDA-approved, revenue-generating or near-launch drugs to plug therapeutic gaps, reducing R\u0026amp;D risk and shortening time-to-market; by Q3 2025 the firm targeted sustaining ~15 commercial assets after 2024 divestitures.\u003c\/p\u003e\n\u003cp\u003eThis buy-and-build model prioritized de-risked acquisitions with positive cash flow—deals since 2022 averaged $45–70M enterprise value—keeping the product mix agile against market shifts through end-2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: FDA-approved or near-launch assets\u003c\/li\u003e\n\u003cli\u003eGoal: ~15 commercial products by Q3 2025\u003c\/li\u003e\n\u003cli\u003eDeal size range: $45–70M EV (2022–2024 average)\u003c\/li\u003e\n\u003cli\u003eBenefit: faster revenue capture, lower R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssertio: $190M FY24, Rolvedon\/Indocin $85M; injectables +28%, 15 products target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAssertio’s product mix centers on specialty branded drugs—Rolvedon and Indocin drove ~$85M of FY2024’s $190M revenue; injectable segment grew ~28% YoY (2024); Cambia\/Zipsor combined ~$57M (2024); goal ~15 commercial assets by Q3 2025; average deal EV $45–70M (2022–2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$190M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop brands (2024)\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectable YoY growth (2024)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCambia+Zipsor (2024)\u003c\/td\u003e\n\u003ctd\u003e$57M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget products (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e~15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg deal EV (2022–24)\u003c\/td\u003e\n\u003ctd\u003e$45–70M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Assertio’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003cp\u003eIdeal for managers, consultants, and marketers seeking a clean, structured breakdown for benchmarking, presentations, or strategy work—editable and ready to impress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Assertio's 4P marketing strategy into a concise, leadership-ready snapshot that speeds decision-making and aligns cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssertio distributes through major wholesalers McKesson, Cardinal Health, and AmerisourceBergen, which together handled over 85% of US pharma wholesale volume in 2024, ensuring national pharmacy reach.\u003c\/p\u003e\n\u003cp\u003eThese partnerships place Assertio products into the national supply chain so pharmacies can stock them; in 2024 timely fills via these hubs supported ~95% on-shelf availability for specialty and primary-care channels.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics through these wholesalers reduce stockouts and cut average fulfillment lead time to ~2–4 days, critical for steady revenue and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAssertio distributes many specialty products through specialty pharmacy channels that handled roughly 60% of specialty drug dispensing in 2024, ensuring cold-chain handling and adherence support for complex regimens.\u003c\/p\u003e\n\u003cp\u003eThese pharmacies offer high-touch services—nurse education, therapy monitoring, prior authorization assistance—reducing abandonment rates by up to 20% and speeding up starts by an average 7 days.\u003c\/p\u003e\n\u003cp\u003eTargeted distribution concentrates supply to narrow patient cohorts, improving dosing accuracy and outcomes while supporting payor reporting and specialty pipeline economics for Assertio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor injectables like Rolvedon, Assertio concentrates distribution on hospitals and outpatient oncology clinics, where 85% of administrations occur per 2024 hospital drug-use data; logistics prioritize cold-chain and same-day delivery to meet high-acuity needs. The company allocates roughly 60% of commercial distribution spend to institutional channels and partners with 120+ specialty distributors to ensure stock availability and reduce stockouts to under 2% at point of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Virtual Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAssertio has optimized distribution for digital health and telemedicine, integrating with EHRs (electronic health records) so clinicians can e-prescribe via remote portals; 2024 partner integrations exceeded 120 platforms, cutting prescription fulfillment time by ~25%.\u003c\/p\u003e\n\u003cp\u003eThis reduces physical steps between prescription and patient receipt, increasing adherence—telemedicine-origin scripts rose 32% YoY in 2024 for specialty meds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ EHR\/telemedicine integrations (2024)\u003c\/li\u003e\n\u003cli\u003e25% faster fulfillment\u003c\/li\u003e\n\u003cli\u003e32% YoY increase in telemedicine scripts (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Retail Pharmacy Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard retail pharmacies stock Assertio’s common prescriptions such as Indocin and Zipsor, enabling broad consumer access across an estimated 40,000 U.S. retail locations as of 2025 and supporting mail-order fulfillment that accounted for ~18% of pharmacy prescription volume in 2024.\u003c\/p\u003e\n\u003cp\u003eThis nationwide footprint helps maximize annual prescription fills—Assertio’s top retail titles contributed to roughly 60% of its 2024 prescription revenue—so retail presence remains core to volume-driven sales strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40,000 U.S. retail locations (2025)\u003c\/li\u003e\n\u003cli\u003eMail-order = ~18% pharmacy volume (2024)\u003c\/li\u003e\n\u003cli\u003eRetail-driven revenue ≈ 60% of 2024 prescription sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssertio: 95% on-shelf, 2–4 day fulfillment, 60% specialty, +32% telemedicine scripts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAssertio uses major wholesalers (McKesson, Cardinal, AmerisourceBergen) for national pharmacy reach, specialty channels and 120+ specialty distributors for injectables, and 120+ EHR integrations to speed e-prescribing; 2024 metrics: ~95% on-shelf availability, 2–4 day lead times, specialty dispensing ~60%, telemedicine scripts +32% YoY, retail footprint ~40,000 locations (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-shelf availability\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulfillment lead time\u003c\/td\u003e\n\u003ctd\u003e2–4 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty dispensing\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelemedicine scripts YoY\u003c\/td\u003e\n\u003ctd\u003e+32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail locations\u003c\/td\u003e\n\u003ctd\u003e~40,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAssertio 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Assertio 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same comprehensive, editable marketing mix analysis you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751060844921,"sku":"assertiotx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/assertiotx-marketing-mix.png?v=1772227362","url":"https:\/\/matrixbcg.com\/products\/assertiotx-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}